PUBLIC COMPANY
save$ATNMActinium Pharmaceuticals, Inc.
$ATNMNew York, NY, USupdated 21d ago
community read0 votes
pipeline
2
marketed
0
phase 3
1
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(2)
pipeline depth2 products
1Phase 21Phase 3
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase3Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML
- phase2Venetoclax and Lintuzumab-Ac225 in AML Patients
- phase2Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) Patients
- phase2Venetoclax, Azacitidine, and Lintuzumab-Ac225 in AML Patients
- phase3Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia
🐶 Hiring Signal
News
no news has mentioned this company yet
Data sources
last refreshed 9m ago
Found something off?
comments(0)
5-min edit window · permanent after that